A research team led by Professor Xiaochun Li of the Institute of Biomedical Precision Testing and Instrumentation at Taiyuan University of Technology, working in collaboration with Director Lizhong Zhang of Shanxi Bethune Hospital, has now unveiled a platform that tackles both halves of this problem at once. Writing in the journal Biomedical Analysis, the team describes a system that pairs a specially engineered microfluidic chip with a deep learning model to enrich and identify rare tumor cells without the use of molecular labels. Dr. Weizhi Liu of Taiyuan University of Technology, Professor Li, and Director Zhang serve as co-corresponding authors, with master’s student Junyi Ouyang as first author and Dr. Haiqin Li also contributing to the study. The work, published under the title Label-free Enrichment and Identification of Circulating Tumor Cells Integrating Inertial Microfluidics and Deep Learning, represents a proof-of-concept demonstration of how physics and artificial intelligence can be woven together into a single analytical pipeline.

The first stage of the platform addresses the separation problem, and it does so by exploiting the most basic physical difference between tumor cells and blood cells: their size. Most conventional CTC isolation techniques depend on antibodies that bind to specific molecules on the surface of tumor cells, most famously the epithelial marker EpCAM. This strategy has a fundamental weakness. Tumor cells are extraordinarily diverse, and different subpopulations of CTCs, particularly those that have undergone a transition toward a more invasive state, may shed or never express the very markers the technology is designed to detect. Cells that lack the marker simply slip through the filter, taking their secrets with them. Label-free approaches sidestep this limitation by relying on intrinsic physical characteristics such as cell diameter and deformability, which are far harder for a cell to disguise.

The chip designed by the Taiyuan team is a spiral microfluidic device containing carefully engineered contraction-expansion structures along its length. The underlying principle is inertial microfluidics, a technique in which fluid flowing through narrow channels at high speed generates lift forces that push cells into predictable equilibrium positions across the channel cross-section. Because CTCs are generally larger than blood cells, with typical diameters of roughly 12 to 25 micrometers compared with 7 to 12 micrometers for white blood cells and 6 to 8 micrometers for red blood cells, each cell population experiences a different balance of forces as it travels through the microchannel. The contraction-expansion geometry amplifies these differences, steering tumor cells and blood cells into separate flow paths so that tumor cells can be collected at a dedicated outlet without any dependence on surface markers.

The team validated the separation concept through computer simulations and laboratory experiments before testing it on artificial blood samples spiked with MCF-7 breast cancer cells and white blood cells. The results were striking. Tumor cells were concentrated at the central outlet while the majority of blood cells were routed toward the side outlets. Quantitatively, the system achieved an MCF-7 cell recovery rate of 89.2 percent, with a standard deviation of 3.1 percent, and a white blood cell removal rate of 86.9 percent, with a standard deviation of 1.4 percent. Perhaps most tellingly, the proportion of tumor cells in the collected fraction rose from 9 percent before separation to 38 percent after enrichment. That fourfold increase in purity dramatically reduces the background the identification stage must contend with, and it does so without staining, labeling, or chemically altering the cells in any way.

Separation, however, is only half the battle. Once the enriched sample has been collected, researchers still face the question of which cells among the mixture are truly tumor cells. In many existing workflows this determination requires fluorescent staining or antibody-based labeling, which adds processing steps, consumes time, requires specialized reagents and equipment, and can compromise the viability or molecular integrity of the very cells researchers hope to study downstream. Fluorescence-based identification also ties the analysis to specific markers, reintroducing at the detection stage the same bias that label-free separation was designed to eliminate. The Taiyuan team’s answer to this dilemma is a deep learning model based on the YOLOv8 architecture, trained to recognize tumor cells directly from ordinary bright-field microscope images, the kind of imagery any standard laboratory microscope can produce.

YOLOv8, whose name stands for You Only Look Once, is a family of object detection models known for speed and accuracy in computer vision tasks. During the development of the platform, fluorescence images were used to establish the ground-truth identity of different cell types and to support the annotation of training data, but once training was complete the model performed all recognition using bright-field images alone. This is a meaningful distinction from many image-analysis approaches that require individual cells to be manually isolated or segmented before classification. YOLOv8 can locate, classify, and count cells directly within complete microscope images, treating the identification task as a single integrated detection problem rather than a multi-step pipeline vulnerable to accumulated error.

The performance figures reported for the identification stage are impressive for a label-free method. The model achieved 96.0 percent overall accuracy in distinguishing tumor cells from non-tumor cells, with precision and recall both at 94.6 percent and specificity at 95.4 percent. In practical terms, this means the system correctly identifies nearly all tumor cells present while rarely misclassifying blood cells as tumor cells, a balance that is critical when the starting population is so heavily skewed toward blood cells. The results demonstrate that artificial intelligence can extract subtle morphological information from standard bright-field images, information that would previously have required fluorescent labeling to access, thereby reducing cost, complexity, and the risk of damaging precious clinical samples.

By combining physical cell sorting with artificial intelligence, the platform addresses the two major bottlenecks that have constrained CTC analysis: finding rare tumor cells in a complex blood environment and recognizing them accurately after enrichment. The label-free workflow may simplify sample processing and, because the cells are never stained or chemically modified, help preserve their integrity for downstream applications such as single-cell sequencing and drug susceptibility testing. Those applications matter enormously, since a viable CTC captured intact can reveal the genetic mutations driving a patient’s tumor and predict which therapies are likely to work before any drug is administered. More broadly, the study illustrates how the marriage of microfluidic technology and deep learning can open new possibilities for analyzing rare biological cells of many kinds, not only tumor cells.

The researchers are careful to frame the current work as a proof of concept rather than a finished clinical tool. The platform was validated using MCF-7 cell lines and artificial blood samples rather than patient-derived clinical samples, and the enrichment and recognition modules have not yet been fully integrated into a single automated system. Future studies, the team says, will focus on evaluating additional tumor types and real patient samples while improving system integration and automation. Corresponding author Xiaochun Li summarized the motivation plainly, noting that the challenge of circulating tumor cell analysis is not only finding these rare cells but also identifying them accurately after separation, and that by combining microfluidics with artificial intelligence the team hopes to provide a simpler and more flexible approach for label-free CTC analysis and future downstream applications. If subsequent validation in clinical samples confirms these early results, the day when a routine blood draw can expose the hidden travelers of metastatic cancer may be considerably closer than it once seemed.

Subject of Research: Label-free detection of circulating tumor cells using inertial microfluidics and deep learning

Article Title: A tiny chip and AI team up to find hidden tumor cells in blood

Article References: A tiny chip and AI team up to find hidden tumor cells in blood. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: circulating tumor cells, liquid biopsy, microfluidics, inertial microfluidics, deep learning, YOLOv8, label-free detection, cancer diagnostics, bright-field imaging, cell sorting, MCF-7, biomedical analysis

The device, developed by Isidora Panez-Toro and colleagues, targets circulating tumor cells, or CTCs, the wandering seeds of metastasis that shed from primary tumors into the bloodstream. These cells are extraordinarily scarce, often fewer than ten per ten milliliters of blood, and they survive in circulation for less than an hour before immune attack and shear stress destroy them. Catching them has long been compared to finding a handful of specific needles in a haystack the size of a stadium. Yet their capture matters enormously, because CTCs carry information about tumor biology that can guide therapy selection and track how a cancer evolves in real time.

The team’s approach rests on a physical phenomenon first described in 1961, when Segré and Silberberg observed that particles flowing through a straight channel migrate, seemingly spontaneously, to orderly lateral positions. Scientists later worked out the forces behind this inertial focusing: a shear-induced lift that pushes particles away from the channel’s centerline and a wall-induced lift that repels them from the walls. When the channel is coiled into a spiral, a secondary rotating flow known as Dean flow adds a drag force that nudges particles sideways. The delicate balance between these lift forces and Dean drag depends on particle size, which means that cells of different dimensions settle into different equilibrium positions and can be steered into separate outlets, purely by fluid dynamics, with no labels, magnets, or lasers.

What distinguishes the new work is its geometry. The researchers built two devices sharing identical inlets, channel cross-sections, and outlet architecture, but with different spiral shapes: a classic Archimedean, or circular, spiral and an oval one. The oval design introduces an oscillation in the radius of curvature with each loop, which modulates the secondary Dean forces and, the authors hypothesized, could sharpen the redistribution of cells and particles. Both chips feature six counterclockwise loops, a rectangular channel 530 micrometers wide and 140 micrometers tall, and three outlets at the periphery. The round spiral’s channel runs 21 centimeters; the oval’s stretches to 25 centimeters, with a short radius of 6.5 millimeters and a long radius of 11 millimeters.

To model blood, the team used fluorescent polystyrene beads of three sizes: 10 micrometers to mimic platelets and red blood cells, 13 micrometers to stand in for white blood cells, and 26 micrometers to represent tumor cells. The beads were suspended in bovine serum albumin solutions chosen to reproduce the density and viscosity of whole blood, which is a non-Newtonian fluid, and the devices were tested under both symmetric flow, with two syringes each delivering 800 microliters per minute, and asymmetric flow, with a fast buffer stream of 2800 microliters per minute meeting a slower particle stream of 600 microliters per minute. Under asymmetric conditions, the round spiral concentrated 13-micrometer beads at the middle outlet with about 90 percent relative isolation, while 26-micrometer beads went to the inner outlet, and the oval chip achieved inner-outlet isolation above 97 percent for the large beads.

The researchers then diluted the carrier fluid, dropping the albumin concentration from 30 percent to 16, 8, and 4 percent to simulate the blood dilution common in other protocols. The results were telling: lower density degraded the focusing of mid-sized particles and, in the oval device, split their distribution between outlets, while large particles remained robustly focused at the inner outlet. In other words, concentrating the sample rather than diluting it preserves the hydrodynamic precision, a finding that runs counter to the widespread practice of diluting blood tenfold or more before microfluidic processing, a step that inflates processing times to hours and risks losing precious cells.

Real cells, however, are not rigid beads. When the team flowed GFP-expressing MNNG-HOS osteosarcoma cells, which average about 17 micrometers in diameter, through the round spiral, the cells behaved like the 13-micrometer particles rather than the 26-micrometer ones, likely because cellular deformability lets them squeeze under hydraulic forces that would deflect a solid bead. The picture grew more complex in whole blood spiked with tumor cells: under asymmetric flow, cells scattered between the middle and outer outlets, an inversion the authors attribute to the sheer number of blood cells overwhelming the equilibrium forces. Switching to symmetric flow restored order, and the oval spiral proved superior, directing 38,026 of 40,000 spiked cells to the inner outlet, compared with 31,657 for the round design.

The decisive breakthrough came from narrowing the channel. A redesigned oval spiral with the width cut from 530 to 320 micrometers, raising the channel’s aspect ratio from 0.26 to 0.43, sharpened the focusing of both particle classes dramatically. In mixed solutions, 13-micrometer beads isolated at the middle outlet with 97.48 percent efficiency and 26-micrometer beads at the inner outlet with 82.73 percent when the albumin concentration was 16 percent. Most importantly, when blood samples were spiked with as few as 500 osteosarcoma cells, the narrower oval chip recovered them at the inner outlet with a relative isolation index of 84.83 percent, and the isolated cells remained viable and kept proliferating in culture afterward, a critical requirement for downstream molecular analysis.

The study is candid about its limits. The team did not directly measure internal pressure or channel deformation in the soft PDMS polymer, and rigid beads cannot fully reproduce the stiffness, buoyancy, and wall interactions of living cells. Residual red blood cells still contaminate the tumor-cell fraction, a problem other groups have tackled by cascading multiple spirals or adding downstream filters. Tumor-cell heterogeneity, with CTC sizes varying by tumor type and within a single sample, means no universal size-based sorter will ever be perfectly pure. The authors suggest that stiffer materials such as polymethyl methacrylate and more physiological cell models will be needed to validate the design’s robustness.

Even so, the implications are considerable. Commercial CTC platforms such as CellSearch and Parsortix achieve good enrichment but involve numerous processing steps and high per-test costs, and most microfluidic alternatives demand red blood cell lysis, centrifugation, or massive dilution before a sample ever reaches the chip. The oval spiral device accepts minimally manipulated blood and delivers enriched tumor cells in under 30 minutes, at the low cost that soft-lithography fabrication allows. If the performance holds in patient samples across tumor types, the technology could become a standard benchtop tool for real-time monitoring of tumor evolution and treatment response, turning a routine blood draw into a window on a cancer’s changing biology.

Subject of Research: Inertial spiral microfluidic separation of circulating tumor cells from liquid biopsies

Article Title: An inertial‐based spiral device for separating rare tumor cells from liquid biopsies

Article References: An inertial‐based spiral device for separating rare tumor cells from liquid biopsies. (n.d.). https://doi.org/10.1002/btm2.70175

Image Credits: AI Generated

DOI: 10.1002/btm2.70175

Keywords: liquid biopsy, circulating tumor cells, microfluidics, inertial focusing, spiral microchannel, Dean flow, cancer detection, cell sorting, osteosarcoma, biomedical engineering, early diagnosis, PDMS